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Rats with a neonatal ventral hippocampal lesion (NVHL) are used to model schizophrenia.
They show enhanced locomotion and difficulties in learning after puberty. Such behavioral
modifications are strengthened by dopaminergic psychostimulant drugs, which is also
relevant for schizophrenia because illustrating its dopaminergic facet. But it remains
questionable that only dopaminergic drugs elicit such effects. The behavioral effects could
simply represent a non specific arousal, in which case NVHL rats should also be hyper-
responsive to other vigilance enhancing drugs. We administered an adenosine (caffeine) or
an adrenaline receptor antagonist, (RX821002) at doses documented to modify alertness
of rats, respectively 5 mg/kg and 1 mg/kg. Rats were selected prior to the experiments
using magnetic resonance imaging (MRI). Each group contained typical and similar NVHL
lesions. They were compared to sham lesioned rats. We evaluated locomotion in a new
environment and the capacity to remember a visual or acoustic cue that announced
the occurrence of food. Both caffeine and RX82100 enhanced locomotion in the novel
environment, particularly in NVHL rats. But, RX82100 had a biphasic effect on locomotion,
consisting of an initial reduction preceding the enhancement. It was independent of the
lesion. Caffeine did not modify the learning performance of NVHL rats. But, RX821002
was found to facilitate learning. Patients tend to intake much more caffeine than healthy
people, which has been interpreted as a means to counter some cognitive deficits. This
idea was not validated with the present results. But adrenergic drugs could be helpful for
attenuating some of their cognitive deficits.
Keywords: animal model of schizophrenia, ventral hippocampal lesion, xanthine, noradrenaline, dopamine,
therapy
INTRODUCTION
Neonatal lesion of the ventral hippocampus (NVHL) in rats
produces an animal model currently used to investigate the devel-
opmental hypothesis of schizophrenia (reviews in: Lipska, 2004;
Tseng et al., 2009). Even if no major damage was found to the
ventral hippocampus in most schizophrenic patients, the model
is still relevant since it involves developmental changes, especially
within the dopaminergic mesocorticolimbic system now consid-
ered central to the model and to the disease (Halim and Swerdlow,
2000). Lesioned animals’ sensitivity to dopaminergic agents is
enhanced, a number of basic emotional reactions are modified,
and cognitive abilities adversely affected (Tseng et al., 2009).
The hypersensitivity to dopaminergic drugs was demonstrated by
administering indirect dopaminergic drugs, such as amphetamine
or cocaine (Lipska et al., 1993; Chambers and Taylor, 2004;
Corda et al., 2006). These drugs, as well as apomorphine a direct
DA agonist, enhanced locomotion (Macedo et al., 2008, 2010;
François et al., 2009; Bychkov et al., 2011; Sandner et al., 2011,
2012) and elicited behavioral modifications in NVHL rats that
had been also documented with the set of tests as used in the
present study (Macedo et al., 2008, 2010; Sandner et al., 2011,
2012).
But, it remains questionable that only dopaminergic drugs
elicit the here over reported effects. Indeed, the behavioral con-
sequence of the neonatal lesion could consist of a non specific
arousal, in which case NVHL rats should also be hyper-responsive
to any vigilance enhancing drug. Therefore we tested two arous-
ing drugs, for instance caffeine, the effect of which only par-
tially involves brain dopaminergic systems (Cauli and Morelli,
2005), and RX821002, a drug that elicits noradrenaline release in
the cortex by blocking alpha2-adrenoautoreceptors in the locus
coeruleus (Fresquet et al., 2007). Increased cortical noradrenaline
release produces arousal and increases vigilance (González and
Aston-Jones, 2006; Laloux et al., 2007). If the disorders elicited
by dopaminergic psychostimulant drugs in NVHL rats exclu-
sively depended on the alteration of the mesolimbic dopamin-
ergic system, other vigilance enhancing drugs would alter less,
or not at all the behavioral characteristics of NVHL rats than
dopaminergic agents. There is an additional reason for having
considered a noradrenergic agent, namely the increasing interest
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in the contribution of noradrenergic neuronal systems in the
behavioral modifications of NVHL rats (Bhardwaj et al., 2004).
Efforts to interpret the modifications of behavior are ham-
pered by rats’ emotional state readily modified by psychoactive
drugs (Shah and Treit, 2003; Degroot and Treit, 2004). Although
we used the lowest efficient doses determined in previous exper-
iments of the two research groups participating to this study
(Nehlig and Boyet, 2000; Fresquet et al., 2007), that were assumed
to have no effect on mood, the question about the contribution
of altered mood state is still relevant insofar as fear attenuation
was demonstrated even in untreated NVHL rats subjected to
the classical Elevated Plus Maze Test for anxiety (Pellow et al.,
1985; Pellow and File, 1986; Macedo et al., 2008; Sandner et al.,
2011; Lecourtier et al., 2012). Therefore this test was added to the
present study.
The NVHL lesions have to be performed at the end of the
first week of life. Their extension can be assessed before adult-
hood using magnetic resonance imaging (MRI), namely before
experiments are conducted (Angst et al., 2007; Macedo et al.,
2008, 2010, 2012; Bertrand et al., 2010; Sandner et al., 2010, 2011,
2012). Selecting rats on the basis of the MRI picture of their lesion
provides optimal reproducibility of the experiments. This allowed
selecting triplets of rats before the experiments which should limit
variability. A member of each triplet received either caffeine, or
RX1002, or saline. We tested the effect of caffeine (5 mg/kg), of
RX821002 (1 mg/kg) and the vehicle in a Locomotion Activity
Test, followed after a 4 days rest period by an Associative Condi-
tioning Test that lasted during the subsequent month. At the end
of the testing period, after 1 week of rest, rats were submitted to
the Elevated Plus Maze Test. We used the same rats in the three
tests. The validity of this method had been previously verified in
experiments that we published in the past few years, finding no
interference from one test to the subsequent one (Angst et al.,




The methodology and protocols were approved by the French
Regional Ethics Committee of Alsace (CREMEAS) under the
reference AL/03/03/02/11. All the procedures were conducted in
accordance with French legislation and EU Directive 2010/63/EU
for animal experiments.
Twelve Sprague Dawley dam rats, each with 8 male pups, were
purchased from Charles River (France), and housed on a 14/10 h
light/dark cycle (lights on at 7 a.m.) with food and water provided
ad libitum. When the pups were 7 days old, they were subjected to
a lesion or sham lesion. MRI pictures of 4 week-old lesioned pups
were then used to select those with bilateral lesions relevant for
the experiments (see Figure 1). Behavioral tests were conducted
in 10–20 week-old adult rats. Thereafter, the rats were killed, and
histology was performed on brain sections to ascertain the exact
extent of the lesion.
SURGERY
Surgical procedures were performed 7 days after birth under
isoflurane anesthesia, as detailed previously (Angst et al., 2007).
FIGURE 1 | Example of lesions according to MRI. The contrasts of the
pictures were inverted so that, opposite to the usual MRI images, the white
matter and bone appear clear and the gray matter dark. With this inversion,
the lesions replaced by cerebrospinal fluid appear black and the sclerosis,
white. They are pointed by black arrows. The pictures in each row
correspond to different coronal slices, the approximate anteriority relative to
the bregma is indicated below. The three rows show an example of a triplet
of lesions. Each row corresponds to one rat before it was treated either
with vehicle, veh; or caffeine, caf; or RX821002. The identity of the rat was
printed on the left most MRI picture (respectively CARX01,02, and 17)
followed by the reference of its experimental group (veh, caf, and RX).
Either 0.3 µL of ibotenic acid (Sigma, France, 10 µg/µL,
pH 7.4), in the case of NVHL rats (N = 62), or 0.3 µL of
artificial cerebrospinal fluid, in the case of sham-lesioned rats
(N = 34), was infused bilaterally into the ventral hippocam-
pus with a 1 µL Hamilton syringe driven by a micro injection
device (type 5000, David Kopf Instruments). The basic com-
mercially available microinjection device was driven by a con-
stant speed electrical motor. The tip of the injection needle was
aimed at the ventral hippocampus (antero-posterior −3.0 mm,
medio-lateral +3.5 mm, and ventro-dorsal −5.0 mm relative to
bregma). After infusion, the needle was left immobile during
3 min. After both infusions, the skin was sutured and rats were
allowed to recover on a heating pad before being returned to
their dam (within 10 min after the end of the surgery). Three
weeks after surgery, rat pups were weaned and housed two
per cage.
SELECTING SUBJECTS USING MRI IMAGING TECHNIQUES
Twenty-one day-old lesioned pups were subjected to an MRI ses-
sion under isoflurane anesthesia. MRI was performed on a small-
animal scanner operating at 4.7 T (TR/TE/TEeff: 3000/30 ms/60
ms). A series of 10 slices (256 × 256 pixels) was generated over a
1 cm long section of the brain, rostral to the cerebellum-cerebrum
gap, as in our previous studies and those conducted by others
(Angst et al., 2007; Macedo et al., 2008, 2010, 2012; Bertrand et al.,
2010; Sandner et al., 2010, 2011, 2012), the purpose being to select
triplets of lesioned rats (1 saline, 1 caffeine and 1 RX821002),
where each member of the triplet had about the same MRI image
in terms of the location and symmetry of the lesion (examples
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are shown in Figure 1). We obtained 9 triplets of lesions (27
lesioned rats), to which we added 27 sham-lesioned controls. Rats
that could not be included in a triplet were transferred to other
research protocols.
Lesioned areas were drawn on MRI coronal sections. The
numbers of pixels of the left and right lesions were summed up
over successive rostro-caudal sections. The sum represents then
the estimated volumes of the lesions. It was submitted to an
ANOVA, with lesion side as within-group factor and treatment
as between-group factor. Another ANOVA was computed on the
sum of left and right lesions with the three rats in each triplet as
within-group factor. The threshold for statistical significance for
all statistical computations was set to p< 0.05.
TREATMENTS
A 3 × 2 experimental design was used (6 groups of 9 rats). The
treatment was applied before each test and each learning session.
The latency between injection and the beginning of the test was 10
min for caffeine (5 mg/kg) and 20 min for RX821002 (1 mg/kg),
dissolved in saline (vehicle: veh) in a final volume of 1 ml and
injected i.p. Control rats received a saline injection 10 or 20 min
before testing. The following groups were considered: 9 NVHL
rats treated with caffeine (caf group), 9 NVHL rats treated with
RX821002 (RX group), and 9 NVHL rats which were given saline
(veh group), plus three groups of 9 sham-lesioned rats which
received the same treatments.
LOCOMOTION
Locomotion was evaluated in eight identical test cages (30 ×
40 cm), which differed from the home cages in several regards:
shape, dimmer light, silent environment, walls with black and
white stripes. A passive infrared detector (IRP 124, Talco, France)
was used to monitor activity during consecutive 5 min periods
for 1 h. The detector comprised a Gallium-Arsenide infra-red
sensitive surface placed behind a Fresnel array and reacted to
the heat emitted by the rat. This array delimited 8 × 3 sectors.
Any movement of the rat from one sector to another triggered
an electric impulse sent to the computer interface. An ANOVA
was computed to analyze the number of beam crossings. The 5
min periods were the within group factor (12 levels). The lesion
(NVHL vs. sham) and treatment (caf vs. RX vs. veh) were the
between group factors. As the situation changed significantly with
time, the total number of beam crossings during the first 20 min
of the test, and during the last 20 min, was subjected to two
separate ANOVAs with the same between-group factors.
ASSOCIATIVE LEARNING TEST
The rats were subjected to a conditioning procedure (Holland and
Petrovich, 2005) which was adapted to characterize the cognitive
effect of NVHL (Macedo et al., 2008). Three days before the
procedure started they were deprived of food during the dark
period. A recessed food dispenser was placed in one wall of an
experimental chamber (25 × 35 cm) in the path of an infrared
photo-beam to detect nose pokes. A light visual cue and loud
speaker were placed above it. A microcomputer delivered cues
or an edible reward (two 45 mg food pellets, Noyes rodent food
pellets, Formula P, New Brunswick, USA) and recorded the breaks
in the photo-beam. The rats were first trained to feed from the
food dispenser. In this preparatory session, no cue was used,
and the reward was given randomly five times in 30 min. The
rats were then subjected to 8 days of two 30-min conditioning
sessions, one in the morning and the other in the afternoon. In
each session, there were five presentations of a 10 s cue, either
light or a tone, immediately followed by the reward (Conditioned
Stimulus (CS+ condition)). The rats were also subjected to a
control condition consisting of five presentations of the other
stimulus, with the food delivery system switched off (CS− con-
dition). All the conditions were balanced: (1) for half of the rats,
the CS+ was the tone, for the other half it was the light; (2)
the morning/afternoon CS+/CS− sessions were spread randomly
across the groups. The average nose-poke duration in the last 5 s
of the 10 s cue was recorded as an index of the rats’ anticipation
of the reward (Holland and Petrovich, 2005). The 5 s period
preceding delivery of the CS served as a control. The total nose
poke duration during these 5 s periods constituted the dependent
variable of an ANOVA where these two periods (pre CS vs. end
of CS) and the series of daily sessions were two within-group
factors, and the lesion and treatment two between-group factors.
We also performed ANOVAs on the mean nose-poke duration
before delivery of the pellets during the first two daily sessions and
the last two daily sessions, with lesion and drug as between-group
factors. This allowed discriminating between learning stage and
final performances of the rats (Angst et al., 2007; Macedo et al.,
2008; Sandner et al., 2011, 2012).
ANXIETY, ELEVATED PLUS MAZE TEST
The rats were subjected to the standard elevated Plus Maze Test
for anxiety (Pellow et al., 1985; Pellow and File, 1986). The maze
consisted of two wooden enclosed arms (50 cm long, 10 cm width,
surrounded by 40 cm high walls), orthogonal to two open arms
(same size as the enclosed walls, with a 2 cm high rim, 80 cm
off the floor. The maze was placed in the same light environment
and the same sound environment as the home cages. There were
external cues around the maze. The rats were placed on a central
platform facing one of the open arms. Their position was recorded
for a period of 10 min. The time spent in the open and enclosed
arms and the number of entries were subjected to ANOVAs, with
the arms (open vs. enclosed) as within-group factor, and lesion
and treatment as two between-group factors.
HISTOLOGY
The rats were given an overdose of pentobarbital (1 ml Doléthal,
Vétoquinol, France). The rostral part of the brain, anterior to
the occipital cortex-cerebellum junction, was immersed in 4%
formalin and used to verify the lesion on 25 µm-thick sections
stained with Cresyl violet.
RESULTS
LESIONED BRAIN AREAS
Photomicrographs representing MRI images of successive sec-
tions of a typical lesion are shown in Figure 1 for a triplet of rats.
The triplet grouping strategy did not reduce the variability of the
volume of brain damaged by the lesion (F(2,16) = 1.48). The global
ANOVA showed there was no significant difference either in lesion
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FIGURE 2 | Locomotion under drug or vehicle. Bar graphs represent
means + S.E.M. of the beam crossings during 20 min. The 6 bars on the
left hand side represent the initial 20 min of the test. The 6 bars on the right
hand side represent the last 20 min. In each group of 6 bars, the 3 left ones
were obtained with sham-lesioned rats and the 3 right ones with NVHL rats
(as indicated below the bars). The white bars represent the effect of the
vehicle, the green one of caffeine and the brown one for RX821002. The
dotted lines ending with two arrows indicate the differences between the
groups that were statistically significant (** p < 0.01; *** p < 0.001).
volumes on each side of the brain (F(1,24) = 1.12) or in treatment
groups (F(2,24) = 0.15).
LOCOMOTION
An ANOVA performed with data pertaining to the whole testing
period found a significant effect of treatment (F(2,48) = 18.15,
p< 0.0001) and time course (F(11,528) = 83.44, p< 0.0001). There
was no global effect of lesion (F(1,48) = 2.13), and no interaction
with the treatment (F(2,48) = 2.61), although it was verging on
significance (p ' 0.08). Given that the treatment interacted sig-
nificantly with time (F(22,528) = 3.92, p < 0.0001) we considered
relevant to analyze the first 20 min separately. The effect of
lesion remained marginal during this period (F(1,48) = 3.19, p '
0.08), but the effect of treatment was significant (F(2,48) = 17.41,
p < 0.001) and interacted significantly with the lesion (F(2,48) =
5.33, p < 0.01). Fisher post-hoc tests revealed differences between
all three treatment groups (caf-veh, P < 0.01; RX-veh, p < 0.01;
caf-RX, p < 0.0001), as illustrated in Figure 2 caffeine enhanced
locomotion and RX821002 reduced it. The picture for the last
20 min was different. The effect of lesion was not significant
(F(1,48) = 0.17) but the effect of treatment was (F(2,48) = 6.40,
p < 0.01), and it did not interact with the lesion (F(2,48) = 0.12).
Fisher post-hoc tests showed that the treatment groups differed
significantly from vehicle (caf-veh, P < 0.001; RX-veh, p < 0.05),
but not from each other (caf-Rx, NS). In the 40–60 min period
locomotion was enhanced by both caffeine and RX821002.
In summary, caffeine enhanced locomotion throughout the
test. Its effect interacted with the enhanced locomotion elicited by
the lesion only for the first 20 min. RX821002 elicited a biphasic
FIGURE 3 | Effect of the treatments in the associative learning test. The
two graphs show the duration of nose poking in the food magazine during
the 5 s before food was delivered (ceiling = 5 s). The X -axis depicts the
sequence of daily training sessions in which 10 s of the cue preceded food
delivery. The Y -axis presents the mean nose poke duration for each daily
session (1–8 days). Data of sham-lesioned rats were represented as circles
and dotted lines, those of NVHL rats as squares and full lines. The white
symbols correspond to the reference data (vehicle), the green symbols to
the effect of caffeine, and the brown symbol to the effects of RX821002.
The standard errors were not plotted for clarity (see statistical computations
in the Result section). The dark backgrounds signal respectively the initial
learning and final stable performances. The arrows point to the changes
(left graph: effect of caffeine on the final performance and, right graph:
effect of RX821002 on the learning stage).
effect, consisting of a reduction and subsequent enhancement of
locomotion, with both phases remaining independent of the effect
of the lesion.
ASSOCIATIVE LEARNING
The results of the rewarded associative learning experiments,
expressed as nose-poke durations in the last 5 s of the conditioned
stimulus (CS+), just before food delivery, are shown in Figure 3.
For the sake of greater clarity, the effect of caffeine (left-hand
graphs) is shown separately from the effect of RX821002 (right-
hand graphs). Values for the CS− control group that stayed close
to zero were not plotted. The two criteria for adequate learning
were statistically met: there was a difference according to whether
or not food was announced by the stimulus (CS+ vs. CS−:
F(1,48) = 262.42, p < 0.0001), as well as a progression—gradual
learning was observed from session to session (F(7,336) = 46.06,
p < 0.0001). The effect of lesion was significant (F(1,48) = 4.13,
p < 0.05), but did not interact globally with treatment (F(1,48) =
0.15). The interaction between treatment and learning chronol-
ogy was significant (F(7,336) = 3.08, p< 0.001). More associations
were required in NVHL rats than their sham-lesioned controls
(Figure 3). This was apparent in the vehicle control groups and
reproduced results from our previous studies (Angst et al., 2007;
Macedo et al., 2008; Sandner et al., 2011). The dynamics of the
effect of caffeine differed from that of RX821002, as demonstrated
by the extra statistical computation, where the learning stage (days
1 and 2) was considered separately from the final stage when most
rats where quasi conditioned and therefore their performance
was stable (days 7 and 8). In the learning stage, the lesion was
not significant (F(1,48) = 2.62), but treatment was (F(2,48) = 3.88,
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p < 0.05), although it did not interact significantly with the
lesion effect (F(2,48) = 0.07). The post-hoc Fisher test revealed that
the effect of RX821002 differed from that of vehicle (RX-veh,
p< 0.05) and caffeine (RX-caf, p< 0.05; caf-veh, NS). RX821002
accelerated the learning rate in both sham-lesioned and NVHL
rats, i.e., independently of the lesion effect. Once learning
was established, the effect of the treatment became significant
(F(2,48) =6.65, p < 0.01), without interacting significantly with
the lesion effect (F(2,48) = 0.24). With RX821002, the final per-
formance of NVHL rats was similar to that of sham-lesioned rats.
The post-hoc Fisher test revealed that the effect of caffeine differed
from that of vehicle (caf-veh, p < 0.001) and RX82002 (RX-caf,
p < 0.05; RX-veh, NS). On the other hand, caffeine reduced the
final performance levels of both sham-lesioned and NVHL rats.
ELEVATED PLUS MAZE
NVHL rats spent more time in the open arms and entered them
more frequently than sham-lesioned rats (Figure 4). For the time
spent in the open arms, the significant factor was lesion (F(1,48) =
39.94, p < 0.0001). Treatment was not significant, neither per se
(F(2,48) = 0.08), nor in interaction with the lesion (F(2,48) = 0.14).
Lesion was also the significant factor for the number of entries
(F(1,48) = 35.84, p < 0.0001). Treatment was not significant,
neither per se (F(2,48) = 3.07, p ' 0.06), nor in interaction
with the lesion (F(2,48) = 2.99, p ' 0.06), but was verging on
significance. Post-hoc statistical analyses provide the explanation
for this marginal effect. The NVHL group of rats which were
given caffeine entered the open arms more frequently than the
other groups (caf-Veh, p < 0.05; caf-RX, p < 0.05; caf-veh, NS),
and had a tendency to enter the enclosed arms more frequently
than the RX group (caf-RX, p ' 0.06). The results illustrate the
anxiolytic effect of the lesion, which persisted independently of
both treatments and caffeine enhanced the number of entries
FIGURE 4 | Results of the Plus Maze Test. Presence of the rats in open
arms is shown in the left bar graph, and number of entries into the arms in
the right bar graph. Each bar represents the mean + S.E.M. The groups of
drugs and rats are similar to those described in Figures 2, 3. The white bars
represent the effect of the vehicle, the green ones that of caffeine and the
brown ones those for RX821002. The dotted lines ending with two arrows
indicate the differences between the groups that were statistically
significant (* p < 0.05; *** p < 0.001).
both into the open and closed arms which may reflect increased
locomotion.
HISTOLOGY
The ventral hippocampus appeared to be damaged exactly as
observed with MRI. In most cases the lesion of the ventral
hippocampus was only partial.
DISCUSSION
COMMENTED SUMMARY OF THE RESULTS
There was no significantly enhanced spontaneous locomotion in
our NVHL rats, which does not mean that this did not exist.
It deserves a brief comment because only a few experiments
found no enhanced locomotion in NVHL rats (Wan et al., 1996).
The increased locomotion reflects a single reaction to a complex
situation where a diversity of factors have to be considered such
as novelty, stress, animal housing and handling conditions, as
well as many other experimental parameters (light and noise). It
depended even on the strain and the sex of the rats (Lipska and
Weinberger, 1995; Beninger et al., 2009). We shall not comment
this point further because our aim was to analyze the reaction to
drugs, not the baseline differences. But this aspect has to be kept
in mind as the unusual drug-induced-state felt by the rat may
trigger locomotion per se by its novelty or stressing properties
(Lipska et al., 1993). Caffeine enhanced locomotion throughout
the testing period, the most prominent enhancement occurring in
the beginning when the environment was new to the rat. Caffeine
did not modify the learning rate. The final performance of the
rats was lower than in controls, meaning they spent less time with
their snout in the food dispenser waiting for food once learning
was acquired. Possibly the caffeine-elicited-fidgetiness could have
prevented these rats from staying quietly with their snout in the
food dispenser. Caffeine and RX821002, did not modify anxiety
as assessed in a Plus Maze Test. RX821002 had a biphasic effect on
locomotion, i.e., a reduction followed by enhancement, with both
remaining independent of the neonatal lesion. Rats learned faster
under RX821001 than under caffeine or vehicle. Each of these
points will be commented in the next chapters of this discussion.
CAFFEINE ENHANCED LOCOMOTION
Caffeine is a mixed antagonist of adenosine A1 and A2A receptors.
At doses that enhance locomotion, adenosine A2 antagonists acti-
vate the same brain areas as dopaminergic agonists, as shown by
c-fos activation and 2-deoxyglucose uptake studies (Svenningsson
et al., 1997; Bennett and Semba, 1998; Nehlig et al., 1998; Nehlig
and Boyet, 2000). These brain areas are anatomically and func-
tionally modified in NVHL rats (Schroeder et al., 1999; Chrapusta
et al., 2003; Corda et al., 2006; O’Donnell, 2010). This anatomo-
functional convergence would easily account for the high sensitiv-
ity of NVHL rats to caffeine as well as the sensitization property
that both drugs share (Simola et al., 2006; Ball and Poplawsky,
2011). Destroying dopaminergic neurons in the nucleus accum-
bens does not block caffeine-induced hyperlocomotion, which
means that the neuronal networks involved in the action of caf-
feine or dopaminergic agents do not overlap (Swerdlow and Koob,
1985). Caffeine also activates midbrain–pontine areas involved
in exploratory locomotion (Groenewegen and Trimble, 2007). It
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stimulates the locus coeruleus and its noradrenergic influence on
neocortical neurons, therefore enhancing vigilance (Aston-Jones
and Cohen, 2005) and, subsequently, locomotion (Svenningsson
et al., 1997; Bennett and Semba, 1998; Nehlig et al., 1998; Nehlig
and Boyet, 2000).
CAFFEINE DID NOT AFFECT FOOD-REWARDED LEARNING
Caffeine did not enhance the learning capacity of normal lab-
oratory animals (Herz, 1999). Learning and memory improve-
ments were reported only in exceptional cases, for instance when
caffeine was administered after the learning stage (Angelucci
et al., 1999, 2002). Caffeine did neither dramatically affect human
performance in learning and memory tasks. Caffeine-enhanced
alertness did not influence motor learning or verbal memory in
healthy human subjects (Kelemen and Creeley, 2001; Mednick
et al., 2008). But, learning seems to be facilitated in tasks where
information was presented passively, and memory performance
would appear to be improved somewhat under suboptimal alert-
ness conditions (Nehlig, 2010). Some studies hinted at its capacity
to reverse pathological memory failures, for instance in rats whose
brains had been damaged (Gevaerd et al., 2001). This was not the
case for NVHL rats in the learning test used for present study.
CAFFEINE DID NOT MODIFY THE LEVEL OF ANXIETY (OR FEAR)
During the initial researches using the Elevated Plus Maze Test,
caffeine showed anxiogenic properties, but very high doses were
administered (Pellow et al., 1985). All studies reporting anxio-
genesis used doses of caffeine above 15 mg/kg in rats (Kayir
and Uzbay, 2006; Park et al., 2010). Anxiogenic effects were also
reported in humans, also at high doses (Jain et al., 2005). But,
paradoxically, when yohimbine, that is anxiogenic in the Elevated
Plus Maze Test, and caffeine were administered together, caffeine
attenuated the anxiogenic effect of yohimbine (Baldwin et al.,
1989). Caffeine also attenuated the anxiogenic effect occurring
after benzodiazepine withdrawal (Baldwin et al., 1989). Thus,
depending on the dose and experimental conditions, caffeine
could be anxiogenic or anxiolytic. In the present experiments, the
time spent in the open arms of the standard Elevated Plus Maze
Test was not affected by caffeine. Furthermore, the anxiolytic
effect produced by the neonatal lesion (Wood et al., 1997; Macedo
et al., 2008; Beninger et al., 2009; Sandner et al., 2011; Lecourtier
et al., 2012) was not sensitive to the effect of caffeine. Nevertheless,
the number of open arm entries were enhanced by caffeine in
NVHL rats. But this is usually seen as an expression of enhanced
activity rather than anxiolysis (Lister, 1987; Silveira et al., 1993;
Bhattacharya et al., 1997; Garcia et al., 2011).
RX821002, AN ALPHA-2 NORADRENERGIC ANTAGONIST, MODIFIED
LOCOMOTION
Inhibition of alpha-2-autoreceptors on cell bodies and dendrites,
for example by administering RX821002, elicits release of nora-
drenaline in the prefrontal cortex (Florin et al., 1994; Fresquet
et al., 2007). Infusing yohimbine, another alpha-2-adrenoceptor
antagonist, into the locus coeruleus where are located the nora-
drenergic neurons innervating the cortex, reduced locomotion
(Weiss et al., 1986). This is what we observed at the beginning
of the locomotion test. But, Darracq et al. (1998) suggested
that alpha-2-autoreceptor antagonists also facilitate dopaminergic
transmission in the nucleus accumbens via a glutamatergic
pathway running from the cortex to the ventral tegmental
area (Darracq et al., 1998). The resulting secondary release of
dopamine in the prefrontal cortex would then stimulate locomo-
tion. This might explain why hyper-locomotion is delayed after
RX821002. However, the dopaminergic neuronal circuits being
modified in NVHL rats, this secondary hyper-locomotion should
be different in NVHL rats compared to sham-lesioned rats, which
was not the case in the present study (Flores et al., 1996, 2005;
O’Donnell, 2010).
AN ALPHA-2-ADRENORECEPTOR ANTAGONIST ACCELERATED
LEARNING
The major finding of this study was that fewer learning ses-
sions were needed when the alpha-2-adrenoreceptor antagonist,
RX821002, was administered. The subsequent enhancement of
learning performance partially compensated for the effect of
the NVHL lesions. This is coherent with the known effects of
another alpha-2-adrenoreceptor antagonist, atipamizole, which
alleviated the deficits in mice whose noradrenergic system had
been damaged as a result of the administration of DSP4 in the
Morris Water Maze Learning Test (Björklund et al., 2000). Nora-
drenergic neurotransmission regulates many aspects of cognition,
including working memory, arousal and attention (Aston-Jones
and Bloom, 1981; Sirviö et al., 1992; Kubiak et al., 1998; Sirviö
and MacDonald, 1999; Bhardwaj et al., 2004; Aston-Jones and
Cohen, 2005). Under conditions of heightened arousal, such as
the response to novelty or behaviorally significant stimuli, locus
coeruleus noradrenergic neurons modulate functioning of the
forebrain structures, such as the hippocampus, thalamus and
cortex mainly, through postsynaptic adrenoreceptors (de Sarro
et al., 1987; McCormick et al., 1991; Björklund et al., 2000).
It will be interesting to further document the contribution of
noradrenaline to the cognitive deficits of the NVHL model and
in patients (Bhardwaj et al., 2004).
THE ALPHA-2-ADRENORECEPTOR ANTAGONIST DID NOT MODIFY THE
LEVEL OF ANXIETY (OR FEAR)
RX821002 did not show any effect in the Elevated Plus Maze
Test, either in sham-lesioned or in NVHL rats. This finding
contrasts with observations of others, but obtained through an
alternate experimental approach. For instance, anxiety assessed by
the Elevated Plus Maze Test, was decreased after reduction of the
expression of alpha-2A-adrenoreceptors in neonatal animals by
means of anti-sense and RNA interference techniques (Shishkina
et al., 2004).
INTERPRETATION OF THE CONTRASTING EFFECTS OF THE TWO
VIGILANCE ENHANCING DRUGS USED
Caffeine enhanced locomotion, a property common to dopamin-
ergic drugs. Given that the other drug, RX821001, did not show
this effect in NVHL rats shows that strengthening the hyper-
locomotion of NVHL rats depends strictly on an hypersensitivity
of brain dopaminergic systems. This reflects this standard point
of view portrayed in the literature (reviews: Lipska, 2004; Tseng
et al., 2009). In the learning test, RX821002 partially reversed the
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deleterious effect of the neonatal lesions, but caffeine did not. This
indicates that the impaired prefrontal noradrenergic innervation
of NVHL rats may contribute to the cognitive disruptions elicited
by the neonatal lesion (Bhardwaj et al., 2004).
CLINICAL RELEVANCE OF THE USE OF ADENOSINE A2 RECEPTOR AND
ADRENALINE ALPHA-2-ADRENORECEPTOR ANTAGONISTS
Increased or excessive coffee intake among patients with
schizophrenia is well documented (Lucas et al., 1990; Gurpegui
et al., 2006; Strassnig et al., 2006). Patients are believed liking
coffee because of the arousing effect of caffeine which may help
to overcome the cognitive disruptions or apathy caused by the
disease or by its medication. However, caffeine has been also
reported to cause psychosis de novo (Shaul et al., 1984) and
to exacerbate the symptoms of schizophrenia (Mikkelsen, 1978;
Lucas et al., 1990).
Contrasting with the lack of improvement in the performance
of rats under caffeine, RX821002, the alpha2-adrenoreceptor
antagonist, improved learning. Research about the contribution
of noradrenergic systems to schizophrenia has yielded inconsis-
tent results (van Kammen and Antelman, 1984; van Kammen
and Kelley, 1991; Yamamoto et al., 1994; Friedman et al., 1999;
Klimek et al., 1999). Interest has been shown, however, in the
prefrontal noradrenergic mechanisms and the potential role of
alpha-2-adrenoreceptor antagonism in the antipsychotic effects of
atypical neuroleptics, particularly considering that co-medication
of fluphenazine with the alpha-2-adrenoreceptor antagonist ida-
zoxan enhanced its antipsychotic and cognitive effectiveness
(Litman et al., 1996). Our results complement these observations,
highlighting the importance of adrenoreceptors as targets for
treating cognitive difficulties like those experienced by patients
with schizophrenia (McAllister, 2001; Masana et al., 2011).
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